ArticleDermatology and therapy2022

Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.

Diamant Thaçi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.